On June 24, 2025, Fosun Pharma held the annual general meeting (AGM) to complete the re-elected and election of the Board of Directors, and the Board of Directors held a meeting on the same day to approve the appointment of the new senior management team. According to the announcement of Fosun Pharma, Mr. Chen Yuqing will serve as Chairman of the Board, Ms. Guan Xiaohui as Co-Chairman of the Board, Mr. Wen Deyong as Vice Chairman of the Board. From June 24, 2025, Mr. Liu Yi will serve as Chief Executive Officer (CEO) and President. Ms. LI Jing, Mr. Xingli Wang, and Mr. Wenjie Zhang will serve as Co-Presidents.

Since its founding over 30 years ago, Fosun Pharma has evolved into a China-rooted, innovation-driven global healthcare group. The new Board of Directors and management team of Fosun Pharma brings solid expertise in the pharmaceuticals, medical devices and diagnostics, and healthcare services industries. Their complementary strengths and comprehensive capabilities form a robust foundation for propelling Fosun Pharma to become a global leader in healthcare innovation integration.

Fosun Pharma places emphasis on the selection and development of young, professional, and internationally minded talent. Building a robust talent pipeline is regarded as a strategic priority for the company's growth. Simultaneously, Fosun Pharma actively attracts top global industry talent, fueling the execution of its strategic initiatives and driving sustainable development forward.

Looking forward, Fosun Pharma will continue to focus on unmet clinical needs, accelerating its innovation transformation and global development. The company is committed to writing a new chapter with new achievements, new results, and new breakthroughs, striving to create greater value for customers, employees, shareholders, partners, and society.